( ing Discovery “This is the first...)Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine,Health

ing Discovery
“This is the first time it has been demonstrated that stimulating the immune system with an autoantigen, such as GAD65, produces a lasting immunological response, even up to 15 months after the initial vaccination”, stated Anders Essen-Möller, President of Diamyd Medical. ”Moreover, the results are consistent with what is expected according to the prevailing theory of how to treat autoimmune disease. This means that the successful clinical effect of Diamyd® administration is starting to be explained immunologically”.

Presentation of Additional Immunological Data and Type II Study Results
Additional immunological data from the type 1 diabetes study will be presented in the latter part of June at the American Diabetes Association Convention (ADA) in Chicago. Importantly, results from a separate clinical study with the Diamyd vaccine in 160 patients with autoimmune type 2 diabetes (LADA) are also planned to be presented at the same ADA Convention.

Initiation of Phase III Clinical Trials
Diamyd plans to initiate phase III studies in newly onset type 1 diabetics later this year. The US study will take place under the direction of Professor Jerry Palmer, and the Principal Investigator of the European study will be Professor Ludvigsson.

About Diamyd Medical:
Diamyd Medical is a life science company developing treatments for diabetes and its complications. The company’s furthest developed project is the GAD-based drug Diamyd® for autoimmune diabetes. Diamyd® has demonstrated significant and positive results in Phase II clinical trials in both type 1 and autoimmune type 2 diabetes patients (LADA) in Sweden.

GAD65, a major autoantigen in autoimmune diabetes, is the active substance in Diamyd®. GAD65 is also an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA. In this context GAD may have an important rol
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Mild Asthma, a Revolutionary Therapy from Italian Research
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
5. Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder
6. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
7. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
8. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
9. Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinsons Patients
10. Heart Attack Patients Treated With Novel Stem Cell Therapy Experience Significant Improvement in Heart and Lung Function
11. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality